Thalia Therapeutics Plc — Lipisiran™ cardiovascular in vitro study completed

(LSE:THAT) Thalia Therapeutics plc announced the successful completion of the Lipisiran™ (THAT-002) in vitro study. The study tested all four constructs of Lipisiran™, with 100% of constructs engaging their targets. The constructs were shown to lower both PCSK9 and Lp(a) as effectively as individual siRNA sequences. The study met its objectives, enabling progression to in vivo studies, which have now commenced. Management described Lipisiran™ as a dual-target, long-duration siRNA. The company stated that this approach could potentially reduce heart attack and stroke risk. Thalia Therapeutics plc referenced Merck KGaA’s proposed acquisition of Silence Therapeutics as evidence of strong market interest in next-generation siRNA Lp(a) therapeutics. The proposed acquisition of Silence Therapeutics by Merck KGaA is valued at approximately US$1.3 billion. The announcement highlights the relevance of Lipisiran™ in the context of industry developments. The company emphasized the effectiveness of its constructs in achieving the intended biological effects. The in vitro study results support further development of Lipisiran™. The company has now initiated in vivo studies following the successful in vitro results. The announcement positions Lipisiran™ as a potential new therapeutic for cardiovascular risk reduction. The company’s management framed the results as a significant milestone for the Lipisiran™ program.